| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Spinal Fusion | 52 | 2025 | 164 | 13.020 |
Why?
|
| Lumbar Vertebrae | 44 | 2025 | 178 | 9.260 |
Why?
|
| Spondylolisthesis | 22 | 2025 | 49 | 7.740 |
Why?
|
| Cervical Vertebrae | 24 | 2026 | 123 | 7.280 |
Why?
|
| Spinal Stenosis | 15 | 2025 | 32 | 5.910 |
Why?
|
| Decompression, Surgical | 19 | 2025 | 71 | 5.730 |
Why?
|
| Spinal Cord Diseases | 12 | 2026 | 44 | 5.180 |
Why?
|
| Spondylosis | 10 | 2024 | 26 | 4.280 |
Why?
|
| Spinal Diseases | 20 | 2026 | 50 | 4.050 |
Why?
|
| Laminectomy | 7 | 2025 | 26 | 3.090 |
Why?
|
| Diskectomy | 10 | 2023 | 38 | 2.820 |
Why?
|
| Practice Guidelines as Topic | 21 | 2020 | 741 | 2.300 |
Why?
|
| Neurosurgery | 8 | 2022 | 31 | 1.760 |
Why?
|
| Registries | 9 | 2025 | 934 | 1.550 |
Why?
|
| Treatment Outcome | 34 | 2025 | 5830 | 1.550 |
Why?
|
| Spinal Cord Compression | 5 | 2018 | 30 | 1.380 |
Why?
|
| Neurosurgical Procedures | 7 | 2026 | 105 | 1.320 |
Why?
|
| Humans | 106 | 2026 | 65826 | 1.250 |
Why?
|
| Carotid Stenosis | 3 | 2020 | 100 | 1.220 |
Why?
|
| Endarterectomy, Carotid | 3 | 2020 | 79 | 1.200 |
Why?
|
| Radiculopathy | 5 | 2025 | 21 | 1.200 |
Why?
|
| Prospective Studies | 15 | 2025 | 3339 | 1.200 |
Why?
|
| Cerebrovascular Circulation | 3 | 2020 | 228 | 1.180 |
Why?
|
| Patient Reported Outcome Measures | 5 | 2025 | 161 | 1.150 |
Why?
|
| Spinal Cord Injuries | 2 | 2021 | 55 | 1.010 |
Why?
|
| Intervertebral Disc Degeneration | 4 | 2016 | 18 | 1.000 |
Why?
|
| Spinal Neoplasms | 2 | 2024 | 16 | 0.990 |
Why?
|
| Middle Aged | 38 | 2026 | 18491 | 0.990 |
Why?
|
| Return to Work | 2 | 2024 | 23 | 0.950 |
Why?
|
| Aged | 29 | 2026 | 15141 | 0.880 |
Why?
|
| Low Back Pain | 8 | 2020 | 113 | 0.860 |
Why?
|
| Laminoplasty | 1 | 2024 | 4 | 0.850 |
Why?
|
| Riluzole | 1 | 2024 | 7 | 0.840 |
Why?
|
| Male | 40 | 2026 | 31398 | 0.840 |
Why?
|
| Cost-Benefit Analysis | 5 | 2019 | 319 | 0.800 |
Why?
|
| Reoperation | 6 | 2016 | 307 | 0.790 |
Why?
|
| Neck Pain | 1 | 2023 | 21 | 0.780 |
Why?
|
| Spine | 8 | 2026 | 55 | 0.750 |
Why?
|
| Deglutition Disorders | 1 | 2023 | 44 | 0.740 |
Why?
|
| Postoperative Complications | 9 | 2026 | 1336 | 0.740 |
Why?
|
| Cognition | 2 | 2020 | 514 | 0.740 |
Why?
|
| Female | 39 | 2026 | 34414 | 0.730 |
Why?
|
| Evidence-Based Medicine | 19 | 2020 | 464 | 0.720 |
Why?
|
| Outpatients | 1 | 2022 | 143 | 0.700 |
Why?
|
| Artificial Intelligence | 3 | 2020 | 216 | 0.700 |
Why?
|
| Intervertebral Disc Displacement | 3 | 2017 | 17 | 0.680 |
Why?
|
| Recovery of Function | 5 | 2024 | 293 | 0.670 |
Why?
|
| Quality of Life | 10 | 2026 | 1267 | 0.660 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2016 | 809 | 0.650 |
Why?
|
| Middle Cerebral Artery | 1 | 2020 | 53 | 0.600 |
Why?
|
| Radiology | 1 | 2022 | 263 | 0.560 |
Why?
|
| Telemedicine | 4 | 2025 | 379 | 0.560 |
Why?
|
| Clinical Trials as Topic | 5 | 2018 | 462 | 0.550 |
Why?
|
| Patient Selection | 6 | 2025 | 484 | 0.550 |
Why?
|
| Models, Economic | 2 | 2016 | 42 | 0.530 |
Why?
|
| Aged, 80 and over | 12 | 2024 | 5681 | 0.520 |
Why?
|
| Disability Evaluation | 8 | 2019 | 216 | 0.500 |
Why?
|
| Intermittent Claudication | 1 | 2017 | 53 | 0.500 |
Why?
|
| Follow-Up Studies | 6 | 2021 | 2496 | 0.490 |
Why?
|
| Costs and Cost Analysis | 2 | 2017 | 106 | 0.470 |
Why?
|
| Sensation Disorders | 1 | 2014 | 23 | 0.430 |
Why?
|
| Lumbosacral Region | 1 | 2013 | 21 | 0.400 |
Why?
|
| Adult | 18 | 2025 | 17567 | 0.400 |
Why?
|
| Spinal Canal | 1 | 2013 | 5 | 0.390 |
Why?
|
| Health Care Costs | 2 | 2016 | 224 | 0.390 |
Why?
|
| Neck | 2 | 2023 | 47 | 0.380 |
Why?
|
| Total Disc Replacement | 1 | 2012 | 3 | 0.370 |
Why?
|
| Neurosurgeons | 2 | 2025 | 8 | 0.360 |
Why?
|
| Mobile Applications | 2 | 2025 | 142 | 0.360 |
Why?
|
| Radiography | 6 | 2021 | 559 | 0.360 |
Why?
|
| United States | 9 | 2026 | 8190 | 0.340 |
Why?
|
| Brain | 2 | 2011 | 1672 | 0.330 |
Why?
|
| Magnetic Resonance Imaging | 7 | 2021 | 2324 | 0.320 |
Why?
|
| Quality of Health Care | 1 | 2014 | 535 | 0.310 |
Why?
|
| Magnetic Resonance Angiography | 3 | 2020 | 202 | 0.300 |
Why?
|
| Predictive Value of Tests | 4 | 2015 | 1117 | 0.290 |
Why?
|
| Spinal Cord | 2 | 2021 | 210 | 0.280 |
Why?
|
| Cerebral Revascularization | 1 | 2008 | 30 | 0.270 |
Why?
|
| Intracranial Embolism | 1 | 2008 | 41 | 0.260 |
Why?
|
| Depression | 2 | 2024 | 910 | 0.250 |
Why?
|
| Eligibility Determination | 1 | 2007 | 37 | 0.250 |
Why?
|
| Hospitals | 1 | 2009 | 399 | 0.250 |
Why?
|
| Cognition Disorders | 1 | 2008 | 224 | 0.240 |
Why?
|
| Minimally Invasive Surgical Procedures | 2 | 2024 | 128 | 0.230 |
Why?
|
| Retrospective Studies | 8 | 2026 | 6953 | 0.230 |
Why?
|
| Health Literacy | 1 | 2026 | 95 | 0.220 |
Why?
|
| Smartphone | 2 | 2023 | 75 | 0.220 |
Why?
|
| Nervous System Diseases | 2 | 2018 | 109 | 0.210 |
Why?
|
| Disease Management | 2 | 2017 | 235 | 0.210 |
Why?
|
| Back Pain | 3 | 2022 | 49 | 0.210 |
Why?
|
| Research Design | 3 | 2017 | 590 | 0.200 |
Why?
|
| Neuroprotective Agents | 1 | 2024 | 80 | 0.200 |
Why?
|
| Pedicle Screws | 1 | 2023 | 4 | 0.200 |
Why?
|
| Quality-Adjusted Life Years | 2 | 2014 | 65 | 0.190 |
Why?
|
| Surgery, Computer-Assisted | 1 | 2023 | 56 | 0.190 |
Why?
|
| Orthopedic Procedures | 2 | 2015 | 55 | 0.190 |
Why?
|
| Time Factors | 4 | 2020 | 3778 | 0.180 |
Why?
|
| Robotics | 1 | 2023 | 86 | 0.180 |
Why?
|
| Regression Analysis | 3 | 2009 | 498 | 0.180 |
Why?
|
| Severity of Illness Index | 2 | 2020 | 1568 | 0.170 |
Why?
|
| Forecasting | 1 | 2022 | 231 | 0.170 |
Why?
|
| Triage | 1 | 2022 | 137 | 0.170 |
Why?
|
| Stents | 2 | 2020 | 501 | 0.170 |
Why?
|
| Healthcare Disparities | 1 | 2026 | 413 | 0.170 |
Why?
|
| Anxiety | 1 | 2024 | 427 | 0.160 |
Why?
|
| Cerebral Angiography | 2 | 2020 | 303 | 0.160 |
Why?
|
| Physical Therapy Modalities | 2 | 2019 | 46 | 0.160 |
Why?
|
| Surveys and Questionnaires | 4 | 2022 | 2790 | 0.160 |
Why?
|
| Range of Motion, Articular | 1 | 2021 | 116 | 0.160 |
Why?
|
| Neoplasm Metastasis | 1 | 2001 | 223 | 0.160 |
Why?
|
| Delivery of Health Care | 2 | 2015 | 439 | 0.160 |
Why?
|
| Asymptomatic Diseases | 1 | 2020 | 52 | 0.150 |
Why?
|
| Robotic Surgical Procedures | 1 | 2023 | 172 | 0.150 |
Why?
|
| Executive Function | 1 | 2020 | 71 | 0.150 |
Why?
|
| Conservative Treatment | 1 | 2019 | 19 | 0.150 |
Why?
|
| Surgical Wound Infection | 2 | 2016 | 126 | 0.150 |
Why?
|
| Clinical Decision-Making | 1 | 2020 | 170 | 0.150 |
Why?
|
| Injections, Epidural | 2 | 2019 | 6 | 0.140 |
Why?
|
| Arteriovenous Malformations | 1 | 1999 | 45 | 0.140 |
Why?
|
| Data Collection | 2 | 2013 | 384 | 0.140 |
Why?
|
| Computed Tomography Angiography | 1 | 2020 | 143 | 0.140 |
Why?
|
| Arthrodesis | 1 | 2018 | 16 | 0.140 |
Why?
|
| Medicare | 1 | 2022 | 629 | 0.140 |
Why?
|
| Histocompatibility Antigens Class II | 5 | 1989 | 179 | 0.140 |
Why?
|
| Internationality | 1 | 2017 | 46 | 0.130 |
Why?
|
| Surgeons | 2 | 2017 | 191 | 0.130 |
Why?
|
| Bone Transplantation | 2 | 2014 | 32 | 0.130 |
Why?
|
| Physiatrists | 1 | 2017 | 1 | 0.130 |
Why?
|
| Bone Screws | 2 | 2014 | 35 | 0.130 |
Why?
|
| Orthopedic Surgeons | 1 | 2017 | 12 | 0.130 |
Why?
|
| Sciatica | 1 | 2017 | 7 | 0.130 |
Why?
|
| Academies and Institutes | 2 | 2017 | 24 | 0.130 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2014 | 1665 | 0.120 |
Why?
|
| Neoplasm, Residual | 1 | 2017 | 53 | 0.120 |
Why?
|
| Feasibility Studies | 2 | 2022 | 593 | 0.120 |
Why?
|
| Case-Control Studies | 1 | 2020 | 1146 | 0.120 |
Why?
|
| Health Resources | 1 | 2017 | 92 | 0.120 |
Why?
|
| Analgesics | 1 | 2017 | 102 | 0.120 |
Why?
|
| Basilar Artery | 1 | 1996 | 34 | 0.120 |
Why?
|
| Guidelines as Topic | 1 | 2017 | 159 | 0.120 |
Why?
|
| Bone Development | 1 | 2016 | 33 | 0.120 |
Why?
|
| Multicenter Studies as Topic | 1 | 2016 | 162 | 0.120 |
Why?
|
| Vancomycin | 1 | 2016 | 40 | 0.120 |
Why?
|
| Aneurysm, Ruptured | 1 | 1996 | 82 | 0.110 |
Why?
|
| Glioblastoma | 1 | 2017 | 161 | 0.110 |
Why?
|
| Subarachnoid Hemorrhage | 1 | 1996 | 110 | 0.110 |
Why?
|
| Wound Healing | 1 | 2016 | 193 | 0.110 |
Why?
|
| Analgesics, Opioid | 1 | 2019 | 533 | 0.110 |
Why?
|
| Spinal Nerve Roots | 1 | 2014 | 18 | 0.110 |
Why?
|
| Program Development | 1 | 2015 | 208 | 0.110 |
Why?
|
| Brain Neoplasms | 2 | 2017 | 321 | 0.110 |
Why?
|
| Bone Substitutes | 1 | 2014 | 16 | 0.110 |
Why?
|
| Orthotic Devices | 1 | 2014 | 12 | 0.110 |
Why?
|
| Monitoring, Intraoperative | 1 | 2014 | 47 | 0.100 |
Why?
|
| Electric Stimulation Therapy | 1 | 2014 | 28 | 0.100 |
Why?
|
| Intraoperative Neurophysiological Monitoring | 1 | 2014 | 6 | 0.100 |
Why?
|
| Patient Outcome Assessment | 1 | 2014 | 56 | 0.100 |
Why?
|
| Patient Protection and Affordable Care Act | 1 | 2014 | 48 | 0.100 |
Why?
|
| Biomedical Research | 1 | 2017 | 263 | 0.100 |
Why?
|
| Postural Balance | 1 | 2014 | 67 | 0.100 |
Why?
|
| Bone Morphogenetic Proteins | 1 | 2014 | 65 | 0.100 |
Why?
|
| Patient Preference | 1 | 2014 | 87 | 0.100 |
Why?
|
| Health Care Reform | 1 | 2014 | 86 | 0.100 |
Why?
|
| Ecological Momentary Assessment | 2 | 2024 | 8 | 0.100 |
Why?
|
| Endovascular Procedures | 1 | 2020 | 633 | 0.100 |
Why?
|
| Nerve Block | 1 | 2014 | 62 | 0.100 |
Why?
|
| Osteogenesis | 1 | 2014 | 154 | 0.100 |
Why?
|
| Societies, Medical | 1 | 2015 | 401 | 0.100 |
Why?
|
| Adolescent | 4 | 2017 | 6367 | 0.090 |
Why?
|
| Joint Instability | 1 | 2013 | 57 | 0.090 |
Why?
|
| Cohort Studies | 2 | 2019 | 2649 | 0.090 |
Why?
|
| Intracranial Aneurysm | 1 | 1996 | 383 | 0.090 |
Why?
|
| Enchondromatosis | 1 | 1991 | 1 | 0.080 |
Why?
|
| Functional Laterality | 1 | 2011 | 141 | 0.080 |
Why?
|
| Chondroma | 1 | 1991 | 3 | 0.080 |
Why?
|
| Skull Neoplasms | 1 | 1991 | 7 | 0.080 |
Why?
|
| Cooperative Behavior | 1 | 2013 | 230 | 0.080 |
Why?
|
| Preoperative Care | 2 | 2024 | 199 | 0.080 |
Why?
|
| Decision Making | 1 | 2014 | 430 | 0.080 |
Why?
|
| Povidone-Iodine | 1 | 1990 | 5 | 0.080 |
Why?
|
| Age Factors | 2 | 2016 | 1595 | 0.080 |
Why?
|
| Neuropsychological Tests | 1 | 2012 | 420 | 0.080 |
Why?
|
| Washington | 1 | 2009 | 24 | 0.080 |
Why?
|
| Economics, Hospital | 1 | 2009 | 15 | 0.080 |
Why?
|
| Young Adult | 3 | 2024 | 4878 | 0.080 |
Why?
|
| Education, Medical, Graduate | 1 | 2013 | 348 | 0.080 |
Why?
|
| Anti-Bacterial Agents | 1 | 2016 | 808 | 0.080 |
Why?
|
| Staphylococcus aureus | 1 | 1990 | 183 | 0.070 |
Why?
|
| Introns | 1 | 1989 | 114 | 0.070 |
Why?
|
| International Classification of Diseases | 1 | 2009 | 136 | 0.070 |
Why?
|
| RNA Processing, Post-Transcriptional | 1 | 1989 | 103 | 0.070 |
Why?
|
| Supine Position | 1 | 2007 | 35 | 0.060 |
Why?
|
| Prone Position | 1 | 2007 | 28 | 0.060 |
Why?
|
| B-Lymphocytes | 1 | 1989 | 565 | 0.060 |
Why?
|
| Health Services Accessibility | 2 | 2026 | 603 | 0.060 |
Why?
|
| Longitudinal Studies | 1 | 2009 | 1291 | 0.060 |
Why?
|
| Length of Stay | 2 | 2021 | 828 | 0.060 |
Why?
|
| Algorithms | 1 | 2009 | 1060 | 0.050 |
Why?
|
| Craniotomy | 2 | 1996 | 20 | 0.050 |
Why?
|
| Chi-Square Distribution | 1 | 2004 | 413 | 0.050 |
Why?
|
| Pain Management | 2 | 2017 | 174 | 0.050 |
Why?
|
| Logistic Models | 2 | 2017 | 1274 | 0.050 |
Why?
|
| Biomedical Technology | 1 | 2023 | 6 | 0.050 |
Why?
|
| Fluoroscopy | 1 | 2023 | 69 | 0.050 |
Why?
|
| Meta-Analysis as Topic | 1 | 2023 | 78 | 0.050 |
Why?
|
| Technology | 1 | 2023 | 53 | 0.050 |
Why?
|
| Receptors, Growth Factor | 1 | 2002 | 19 | 0.050 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2002 | 61 | 0.040 |
Why?
|
| Self Report | 1 | 2024 | 395 | 0.040 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2002 | 169 | 0.040 |
Why?
|
| Physicians | 1 | 2007 | 486 | 0.040 |
Why?
|
| Diagnosis, Differential | 2 | 1996 | 995 | 0.040 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 1996 | 715 | 0.040 |
Why?
|
| Epidemiologic Methods | 1 | 2019 | 67 | 0.040 |
Why?
|
| Monte Carlo Method | 1 | 2019 | 102 | 0.040 |
Why?
|
| Inappropriate Prescribing | 1 | 2019 | 68 | 0.040 |
Why?
|
| Cavernous Sinus | 1 | 1999 | 10 | 0.040 |
Why?
|
| Reproducibility of Results | 1 | 2022 | 1720 | 0.030 |
Why?
|
| Pregabalin | 1 | 2017 | 4 | 0.030 |
Why?
|
| Electronic Mail | 1 | 2017 | 46 | 0.030 |
Why?
|
| T-Lymphocytes | 2 | 1994 | 1012 | 0.030 |
Why?
|
| Mutation | 3 | 1989 | 2674 | 0.030 |
Why?
|
| Resource Allocation | 1 | 2015 | 20 | 0.030 |
Why?
|
| Blood Loss, Surgical | 1 | 2016 | 65 | 0.030 |
Why?
|
| Comparative Effectiveness Research | 1 | 2015 | 47 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 2 | 2002 | 426 | 0.030 |
Why?
|
| Brazil | 1 | 2015 | 104 | 0.030 |
Why?
|
| Propensity Score | 1 | 2016 | 192 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2017 | 757 | 0.030 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2017 | 202 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2017 | 932 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2022 | 2737 | 0.030 |
Why?
|
| Photogrammetry | 1 | 2014 | 2 | 0.030 |
Why?
|
| Base Sequence | 4 | 1989 | 1332 | 0.030 |
Why?
|
| Contraindications | 1 | 2014 | 52 | 0.030 |
Why?
|
| Cost of Illness | 1 | 2015 | 169 | 0.030 |
Why?
|
| Intervertebral Disc | 1 | 2014 | 21 | 0.030 |
Why?
|
| Electromyography | 1 | 2014 | 100 | 0.030 |
Why?
|
| Antigen-Presenting Cells | 3 | 1989 | 180 | 0.030 |
Why?
|
| Patient Care Planning | 1 | 2014 | 85 | 0.030 |
Why?
|
| Molecular Sequence Data | 4 | 1989 | 1980 | 0.030 |
Why?
|
| Qualitative Research | 1 | 2018 | 763 | 0.020 |
Why?
|
| Quality Assurance, Health Care | 1 | 2015 | 253 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2017 | 1029 | 0.020 |
Why?
|
| Brain Diseases | 1 | 1994 | 76 | 0.020 |
Why?
|
| Positron-Emission Tomography | 1 | 2014 | 233 | 0.020 |
Why?
|
| Pain Measurement | 1 | 2014 | 344 | 0.020 |
Why?
|
| Quality Control | 1 | 2013 | 79 | 0.020 |
Why?
|
| Certification | 1 | 2013 | 58 | 0.020 |
Why?
|
| Attitude of Health Personnel | 1 | 2017 | 633 | 0.020 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2017 | 770 | 0.020 |
Why?
|
| Opioid-Related Disorders | 1 | 2019 | 532 | 0.020 |
Why?
|
| Patient Care | 1 | 2013 | 79 | 0.020 |
Why?
|
| Lymphoma | 2 | 1989 | 101 | 0.020 |
Why?
|
| Cloning, Molecular | 2 | 1989 | 386 | 0.020 |
Why?
|
| Patient Readmission | 1 | 2016 | 452 | 0.020 |
Why?
|
| Animals | 7 | 2016 | 21489 | 0.020 |
Why?
|
| Prognosis | 1 | 2016 | 1792 | 0.020 |
Why?
|
| Cartilage | 1 | 1991 | 35 | 0.020 |
Why?
|
| Transfection | 2 | 1989 | 700 | 0.020 |
Why?
|
| Povidone | 1 | 1990 | 8 | 0.020 |
Why?
|
| Patient Satisfaction | 1 | 2013 | 442 | 0.020 |
Why?
|
| Microbial Sensitivity Tests | 1 | 1990 | 207 | 0.020 |
Why?
|
| Temperature | 1 | 1990 | 317 | 0.020 |
Why?
|
| Staphylococcal Infections | 1 | 1990 | 131 | 0.020 |
Why?
|
| Mice | 6 | 2002 | 11185 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2016 | 2329 | 0.020 |
Why?
|
| RNA Splicing | 1 | 1989 | 173 | 0.020 |
Why?
|
| Intracellular Fluid | 1 | 1988 | 32 | 0.020 |
Why?
|
| Body Fluids | 1 | 1988 | 21 | 0.020 |
Why?
|
| Cytoplasm | 1 | 1989 | 283 | 0.020 |
Why?
|
| Antigens, Surface | 1 | 1988 | 199 | 0.020 |
Why?
|
| Skin | 1 | 1990 | 436 | 0.020 |
Why?
|
| Phenotype | 1 | 1989 | 1236 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 1989 | 1583 | 0.010 |
Why?
|
| Cell Line | 2 | 2002 | 2031 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factors | 1 | 2002 | 22 | 0.010 |
Why?
|
| Endothelial Growth Factors | 1 | 2002 | 22 | 0.010 |
Why?
|
| Lymphokines | 1 | 2002 | 67 | 0.010 |
Why?
|
| Cell Line, Transformed | 1 | 2002 | 97 | 0.010 |
Why?
|
| Signal Transduction | 2 | 1989 | 3168 | 0.010 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2002 | 37 | 0.010 |
Why?
|
| 3T3 Cells | 1 | 2002 | 111 | 0.010 |
Why?
|
| Amino Acid Sequence | 3 | 1989 | 1589 | 0.010 |
Why?
|
| Child | 1 | 1991 | 4653 | 0.010 |
Why?
|
| HeLa Cells | 1 | 2002 | 541 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2002 | 234 | 0.010 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2002 | 282 | 0.010 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2002 | 679 | 0.010 |
Why?
|
| Membrane Proteins | 1 | 2002 | 926 | 0.010 |
Why?
|
| Protein Conformation | 2 | 1988 | 793 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2002 | 3504 | 0.010 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 1994 | 39 | 0.010 |
Why?
|
| Cell Movement | 1 | 1994 | 484 | 0.010 |
Why?
|
| Bucladesine | 1 | 1989 | 6 | 0.000 |
Why?
|
| Fixatives | 1 | 1989 | 16 | 0.000 |
Why?
|
| Protein Kinase C | 1 | 1989 | 102 | 0.000 |
Why?
|
| Hybridomas | 1 | 1988 | 63 | 0.000 |
Why?
|
| Epitopes | 1 | 1989 | 291 | 0.000 |
Why?
|
| Antigenic Variation | 1 | 1988 | 7 | 0.000 |
Why?
|
| Genes, MHC Class II | 1 | 1988 | 36 | 0.000 |
Why?
|
| Cytosol | 1 | 1989 | 184 | 0.000 |
Why?
|
| Biological Transport | 1 | 1988 | 292 | 0.000 |
Why?
|
| Lymphocyte Activation | 1 | 1989 | 755 | 0.000 |
Why?
|
| Mice, Inbred BALB C | 1 | 1988 | 869 | 0.000 |
Why?
|
| Peptide Fragments | 1 | 1988 | 419 | 0.000 |
Why?
|
| Cell Nucleus | 1 | 1989 | 634 | 0.000 |
Why?
|
| Peptides | 1 | 1989 | 593 | 0.000 |
Why?
|
| DNA | 1 | 1988 | 853 | 0.000 |
Why?
|